Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.

Corrado Pelaia Claudia Crimi Santi NolascoGiovanna Elisiana CarpagnanoRaffaele BrancaccioEnrico BuonamicoRaffaele CampisiClaudia GaglianiVincenzo PatellaGirolamo PelaiaGiuseppe ValentiNunzio Crimi

Published in: Biomedicines (2021)

The results of this real-life study suggest that the pharmacologic shift from omalizumab to benralizumab can be a valuable therapeutic approach for allergic patients with severe eosinophilic asthma, not adequately controlled by anti-IgE treatment.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
early onset
drug induced
cystic fibrosis
atopic dermatitis
air pollution